Quick Overview
- ARK Invest expanded holdings in Figma, Arcturus Therapeutics, and 10x Genomics during last week’s trading—representing the fund’s complete purchase activity
- The investment firm acquired 337,381 Figma shares worth more than $8.1 million on March 20
- Circle Internet Group faced selloffs totaling nearly $5.9 million across ARKK and ARKW, with 45,998 shares divested
- Figma’s stock price sits 83% below 2025 peak levels even as the company posted 40% quarterly revenue expansion
- Additional divestments included positions in Teradyne, Bullish, Guardant Health, and Butterfly Network
Cathie Wood, who leads ARK Invest as founder and CEO, executed a remarkably focused investment strategy last week, making purchases in only three securities as equity markets experienced their fourth consecutive weekly decline. All three primary market benchmarks recorded losses throughout this timeframe.
Wood’s restrained purchasing pattern caught investor attention, particularly given her historical tendency to increase buying activity when markets experience downward pressure.
Her investment selections comprised Figma, Arcturus Therapeutics, and 10x Genomics. Simultaneously, ARK divested holdings across multiple companies, notably Circle Internet Group, which operates in the cryptocurrency sector.
Figma operates a cloud-native design platform serving professionals creating websites, applications, and various digital products. ARK accumulated 337,381 shares on March 20 through its ARKK and ARKW exchange-traded funds, representing a total investment of $8,171,367.
The company’s shares have declined 83% from last summer’s high point, following a remarkable rally that saw the stock price more than quadruple from its initial public offering price of $33. The steep correction occurred despite Figma delivering 40% revenue expansion in its latest quarterly report, accelerating from 38% growth in the prior period.
The platform’s net dollar-retention metric reached 136%, indicating that current customers increased their spending by 36% year-over-year. This figure represents the highest performance in this category over the past two years.
Wall Street forecasters anticipate revenue growth moderating to 30% during the current year and further slowing to 20% in the following year. The absence of robust profitability metrics has created headwinds for the stock’s performance.
Cryptocurrency Exposure Trimmed Through Circle Internet Sale
Within the digital asset space, ARK liquidated 45,998 Circle Internet Group shares distributed between ARKK and ARKW portfolios, generating $5,902,923 in proceeds. The firm had been systematically reducing this position throughout the week.
Circle Internet maintains significant operations in the cryptocurrency infrastructure sector, particularly through its involvement with the USD Coin stablecoin framework.
ARK additionally divested 19,206 Teradyne shares for $5,807,894, alongside 103,379 Bullish shares worth $4,093,808 and 9,621 Guardant Health shares generating $857,038. The firm also sold 182,353 Butterfly Network shares for $723,941.
Biotechnology Selections: Arcturus and 10x Genomics
Arcturus Therapeutics focuses on messenger RNA platforms to create therapies addressing uncommon respiratory and hepatic conditions. ARK increased its Arcturus position during three separate trading sessions last week, culminating with a Friday purchase of 22,773 shares valued at $153,034 through the ARKG fund.
The company has experienced consecutive annual revenue contractions spanning three years, with analysts projecting further declines extending into 2026. Recent developments include management’s announcement extending the company’s financial runway through at least the second quarter of 2028.
10x Genomics manufactures specialized instruments for life sciences research, featuring its signature Chromium technology designed for single-cell genomic examination. ARK accumulated 192,658 shares throughout the week across ARKK and ARKG portfolios, totaling $3,541,054.
The company’s shares debuted at $38 during its public market launch and currently trade near half that valuation. Profitability remains elusive, while management’s 2026 projections indicate potential revenue contraction when accounting for licensing revenue generated from prior-year patent settlement agreements.
